Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma

被引：0
|
作者：
Steven I. Park
Carolina P. Lin
Natalie Ren
Steven P. Angus
Dirk P. Dittmer
Michael Foote
Trevor Parton
Aadra P. Bhatt
Yuri D. Fedoriw
Daniel P. Roth
Marissa L. Cann
Gary L. Johnson
Blossom Damania
机构：
[1] Levine Cancer Institute,UNC School of Medicine
[2] Atrium Healthcare,undefined
[3] University of North Carolina Lineberger Comprehensive Cancer Center,undefined
来源：
Targeted Oncology | 2019年 / 14卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：563 / 575
页数：12
相关论文
共 20 条
  • [1] Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma
    Park, Steven I.
    Lin, Carolina P.
    Ren, Natalie
    Angus, Steven P.
    Dittmer, Dirk P.
    Foote, Michael
    Parton, Trevor
    Bhatt, Aadra P.
    Fedoriw, Yuri D.
    Roth, Daniel P.
    Cann, Marissa L.
    Johnson, Gary L.
    Damania, Blossom
    TARGETED ONCOLOGY, 2019, 14 (05) : 563 - 575
  • [2] Alisertib, an Aurora a Kinase Inhibitor, Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma Cells
    Park, Steven I.
    Lin, Carolina P.
    Dittmer, Dirk P.
    Angus, Steven P.
    Wang, Greg G.
    Fedoriw, Yuri D.
    Darr, David B.
    Roth, Daniel P.
    Sharpless, Norman E.
    Damania, Blossom
    BLOOD, 2015, 126 (23)
  • [3] Dual Inhibition of Aurora Kinase and BRD4 Leads to Improved Anti-Tumor Activity in Myc-Overexpressing Lymphoma Cells
    Park, Steven I.
    Lin, Carolina
    Druhan, Lawrence J.
    Foote, Michael B.
    Parton, Trevor
    Ren, Natalie
    Angus, Steven P.
    Bhatt, Aadra P.
    Jaros, Scott C.
    Ghosh, Nilanjan
    Jacobs, Ryan
    Avalos, Belinda Rene
    Dittmer, Dirk P.
    Sharpless, Norman E.
    Damania, Blossom A.
    BLOOD, 2017, 130
  • [4] Enhancing therapies for MYC-overexpressing Non-Hodgkin's lymphoma: A role for MYC downregulation and new combination therapies
    Psaras, Alexandra Maria
    Brooks, Tracy Ann
    CANCER RESEARCH, 2020, 80 (16)
  • [5] Multitarget approach against PI3K, Aurora kinase, and BRD4 leads to improved antitumor activity in Myc-overexpressing lymphoma cells
    Park, Steven I.
    Lin, Carolina P.
    Foote, Michael
    Parton, Trevor
    Darr, David B.
    Roth, Daniel
    Bhatt, Aadra P.
    Dittmer, Dirk P.
    Sharpless, Norman E.
    Damania, Blossom
    MOLECULAR CANCER RESEARCH, 2015, 13
  • [6] ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells
    Kwok, Marwan
    Davies, Nicholas
    Agathanggelou, Angelo
    Smith, Edward
    Oldreive, Ceri
    Petermann, Eva
    Stewart, Grant
    Brown, Jeff
    Lau, Alan
    Pratt, Guy
    Parry, Helen
    Taylor, Malcolm
    Moss, Paul
    Hillmen, Peter
    Stankovic, Tatjana
    BLOOD, 2016, 127 (05) : 582 - 595
  • [7] Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma
    Diaz, Roberto Jose
    Golbourn, Brian
    Faria, Claudia
    Picard, Daniel
    Shih, David
    Raynaud, Denis
    Leadly, Michael
    MacKenzie, Danielle
    Bryant, Melissa
    Bebenek, Matthew
    Smith, Christian A.
    Taylor, Michael D.
    Huang, Annie
    Rutka, James T.
    ONCOTARGET, 2015, 6 (05) : 3359 - 3374
  • [8] Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer
    Kunder, Ratika
    Velyunskiy, Michelle
    Dunne, Sara F.
    Cho, Byoung-Kyu
    Kanojia, Deepak
    Begg, Lauren
    Orriols, Adrienne M.
    Fleming-Trujillo, Erica
    Vadlamani, Pranathi
    Vialichka, Alesia
    Bolin, Rosemary
    Perrino, Jessica N.
    Roth, Diane
    Clutter, Matthew R.
    Zielinski-Mozny, Nicolette A.
    Goo, Young Ah
    Cristofanilli, Massimo
    Mendillo, Marc L.
    Vassilopoulos, Athanassios
    Horiuchi, Dai
    CELL CHEMICAL BIOLOGY, 2022, 29 (03) : 358 - +
  • [9] PIM1 kinase inhibition halts the growth of MYC-overexpressing triple-negative breast tumors
    Horiuchi, Dai
    Zhou, Alicia Y.
    Corella, Alexandra N.
    Yau, Christina
    Lawson, Devon A.
    Bazarov, Alexey V.
    Yaswen, Paul
    McManus, Michael T.
    Werb, Zena
    Welm, Alana L.
    Goga, Andrei
    CANCER RESEARCH, 2014, 74 (19)
  • [10] MECHANISM OF ACTION AND THERAPEUTIC APPLICATION OF AURORA KINASE B INHIBITION IN c-MYC OVEREXPRESSING MEDULLOBLASTOMA
    Diaz, Roberto
    Golbourn, Brian
    Faria, Claudia
    Shih, David
    MacKenzie, Danielle
    Picard, Daniel
    Bryant, Melissa
    Smith, Christian
    Taylor, Michael
    Huang, Annie
    Rutka, James
    NEURO-ONCOLOGY, 2013, 15 : 20 - 20
12